Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin + toripalimab + FOLFOX4 perioperative study in HER2-expressing locally advanced gastric cancer
ChiCTR2400079986Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin, toripalimab and oxaliplatin + fluorouracil + leucovorin in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Zhejiang Cancer Hospital. Primary endpoint: pathologic complete response. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
disitamab vedotintoripalimaboxaliplatin + fluorouracil + leucovorin
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400079986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079986.